Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNPR-101-DFO*-89Zr PET/CT Imaging in Solid Tumors
NCT06337084Phase 1Active, not recruiting
- Sponsor
- Monopar Therapeutics Inc.
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MNPR-101 in solid tumor, sponsored by Monopar Therapeutics Inc. Primary endpoints: Dosimetry and Biodistribution of MNPR-101-DFO*-89Zr, Tumor Standard Uptake Value and 1 more. Started May 2024; status: active, not recruiting.
02
Drugs
MNPR-101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06337084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337084.